Overview

Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)

Status:
Completed
Trial end date:
2019-03-11
Target enrollment:
Participant gender:
Summary
Inhaled corticosteroids (ICS) are considered first-line treatment for persistent asthma, yet little is known about the genetic factors that influence response to this therapy. This study seeks to quantify response to ICS therapy in African American and white patients, as well as look for genetic markers that predict treatment response.
Phase:
N/A
Details
Lead Sponsor:
Henry Ford Health System
Treatments:
Beclomethasone